摘要:
17 beta-HSD1 is a novel target for the treatment of estrogen-dependent diseases, as it catalyzes intracellular estradiol formation. Starting from two recently described compounds, highly active and selective inhibitors were developed. Benzoyl 6 and benzamide 17 are the most selective compounds toward 17 beta-HSD2 described so far. They also showed a promising profile regarding activity in T47-D cells, selectivity toward ER alpha and ER beta inhibition of hepatic CYP enzymes, metabolic stability, and inhibition of marmoset 17 beta-HSD1 and 17 beta-HSD2.